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New YorkABSTRACT Mechanical properties of the tumor microenvironment have emerged as key factors in tumor progression. It has
been proposed that increased tissue stiffness can transform stromal fibroblasts into carcinoma-associated fibroblasts. However,
it is unclear whether the three to five times increase in stiffness seen in tumor-adjacent stroma is sufficient for fibroblast
activation. In this study we developed a three-dimensional (3D) hydrogel model with precisely tunable stiffness and show
that a physiologically relevant increase in stiffness is sufficient to lead to fibroblast activation. We found that soluble factors
including CC-motif chemokine ligand (CCL) chemokines and fibronectin are necessary for this activation, and the combination
of C-C chemokine receptor type 4 (CCR4) chemokine receptors and b1 and b3 integrins are necessary to transduce these
chemomechanical signals. We then show that these chemomechanical signals lead to the gene expression changes associated
with fibroblast activation via a network of intracellular signaling pathways that include focal adhesion kinase (FAK) and phosphoi-
nositide 3-kinase (PI3K). Finally, we identify the actin-associated protein palladin as a key node in these signaling pathways that
result in fibroblast activation.INTRODUCTIONTumors are generally much stiffer than normal tissue. Breast
cancer tumors have been shown to be 10 to 20 times stiffer
than normal breast tissue. The stromal tissue surrounding
the tumor, known as the tumor microenvironment (TME),
is also typically stiffer than normal tissue, although usually
only three to five times stiffer than normal stroma (1,2). This
increase in stromal stiffness has been implicated in changes
in both tumor cells and in tumor associated stromal cells
such as fibroblasts, which are sensitive to mechanical prop-
erties of the extracellular matrix (ECM) (1–8).
Fibroblasts are the workhorses of stromal tissue. They are
responsible for building and remodeling the ECM and also
have critical roles in wound healing, the regulation of
inflammation, and control of epithelial differentiation
(4,9). In the TME, fibroblasts are activated to a myofibro-
blast-like phenotype, commonly referred to as carcinoma-
associated fibroblasts (CAFs), and frequently undergo
genetic mutations such as tumor cells (9–11). Myofibro-
blasts are characterized by their elongated spindle-like
morphology and contractile phenotype, as well as by
changes in patterns of protein expression, including in-
creases in a-smooth muscle actin (aSMA), fibroblast activa-
tion protein (FAPa), the EDA splice variant of fibronectin
(FN-EDA), and palladin, which together can be used to
identify differentiated myofibroblasts (9–12). These acti-
vated fibroblasts are thought to play key roles in promotingSubmitted May 11, 2015, and accepted for publication June 17, 2015.
*Correspondence: ligonl@rpi.edu
Editor: Alissa Weaver.
 2015 by the Biophysical Society
0006-3495/15/07/0249/16 $2.00both tumor growth and metastasis by paracrine and juxta-
crine interactions with both tumor and other tumor associ-
ated cells (9–14).
Both soluble factors such as TGFb and increases in
matrix stiffness have been shown to contribute to fibroblast
activation (5,6,15,16). Similarly, three-dimensional (3D)
matrices derived from CAFs can induce fibroblast activation
and the maintenance of this phenotype is dependent on
matrix interactions (17,18). Some studies have shown that
increased stiffness alone can lead to an activated fibroblast
phenotype, but these studies were done in two-dimensional
(2D) culture and examined the effects of very large changes
in stiffness, rather than the more subtle changes seen in the
TME (4,15), so it remains unclear if the physiological stiff-
ness associated with the TME is sufficient to cause fibroblast
activation.
Collagen-I is the major component of the breast stroma.
To develop a biomimetic 3D culture environment, we devel-
oped a collagen-I hydrogel system in which we can tune
mechanical stiffness (19,20). The stiffness of a collagen-I
hydrogel can be altered by varying parameters involved
in the formation of the hydrogel such as pH, tempera-
ture, and collagen concentration (19,21,22), but these
methods alter the structure and/or ligand availability of
the collagen-I, potentially inducing changes in cell pheno-
type independent of the changes in stiffness. To avoid this
complication, we developed a system in which we can con-
trol the hydrogel stiffness independently of collagen con-
centration, gelation temperature, or pH by cross-linking
the collagen with short (12-atom) bio-inert polyethylenehttp://dx.doi.org/10.1016/j.bpj.2015.06.033
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addition of N-hydroxysuccinimide groups—poly(ethylene
glycol)-di(succinic acid N-hydroxysuccinimide ester
(PEG-diNHS). PEG-diNHS can cross-link collagen-I fibrils
by forming amide bonds to tether collagen molecules
together, mimicking the physiological cross-links formed
in vivo (23). These collagen-I PEG-diNHS hydrogels have
been previously used in studies of tumor spheroid formation
and in tissue engineering, and show good biocompatibility
(24,25).
Palladin is an actin associated Ig-domain protein that is
overexpressed in many cancers and particularly in CAFs
(26–32). Palladin has been shown to regulate actin dynamics
and adhesion formation (30,32). It can cross-link actin fila-
ments directly (33), as well as bind to multiple actin associ-
ated proteins such as VASP (34), profilin (35), and a-actinin
(36). Palladin is associated with mechanosensitive struc-
tures such as focal adhesions (37) and stress fibers (32), sug-
gesting that it may play a role in cellular mechanosensation
or the transduction of mechanical signals. More recently,
palladin has also been shown to act as a transcriptional regu-
lator, controlling the expression of smooth muscle cell genes
such as aSMA (12,38,39). Palladin has been shown to
localize to the nucleus in some cell types, which may be
consistent with its role in transcription (40,41) but the regu-
lation and balance of these two distinct roles in the actin
cytoskeleton and in transcription remains unclear (42).
However, these two roles of palladin in both transcriptional
regulation and mechanosensation make it a strong candidate
to play a key role in the regulation of fibroblast activation by
mechanical signals.
In this study we sought to test whether the modest three
to five times increase in stiffness seen in the TME is suffi-
cient to activate fibroblasts to a myofibroblast-like state.
We observed changes in morphology and gene expression
consistent with activation when cells were embedded in
stiffened 3D hydrogels, but that the presence of soluble fac-
tors including CC-motif chemokine ligand (CCL) chemo-
kines and fibronectin were necessary for activation. We
found that these chemomechanical signals were transduced
via the C-C chemokine receptor type 4 (CCR4) chemokine
receptor and b1 and b3 integrins, which then signal to intra-
cellular signaling pathways that include focal adhesion ki-
nase (FAK) and phosphoinositide 3-kinase (PI3K). Finally,
we show that the actin-associated protein palladin is a key
node in this network of signaling that results in fibroblast
activation.MATERIALS AND METHODS
Cells and cell maintenance
Human fibroblast cells CCD-1065Sk (product ATCC CRL-2077, American
Type Culture Collection) were cultured in T-175 flasks in MEM (Corning/
Mediatech, Manassas, VA) supplemented with 10% fetal bovine serum
(Atlanta Biologicals, Norcross, GA), 1% L-glutamine (Corning), 1 mMBiophysical Journal 109(2) 249–264sodium pyruvate (Corning), and 1% penicillin/streptomycin (Corning)
and maintained at 5% CO2. Media was replaced two to three times a
week during standard cell culture. Cells were cultured from a minimum
of 10% to a maximum of 75% confluence and only cells from passages 2
to 8 were used.Experimental conditions
For reduced serum experiments, cells were cultured in reduced serum (1%)
media (RSM) for 3 days before hydrogel encapsulation. After encapsula-
tion, fresh RSM was added to hydrogels. All conditions received fresh
media at the beginning of the 3 day experimental time course, and media
was not replaced during experimental time course. For 2D experimental
samples, 100,000 cells were seeded into 10 cm culture dishes (product
172958, Thermo Scientific, Waltham, MA). Collagen-coated 2D dishes
were coated with collagen-I solution (product C9791, Sigma-Aldrich,
St. Louis, MO) at 10 mg/mL overnight at 37C. Solution was aspirated,
and dishes were allowed to dry under ultraviolet illumination before use.Preparation of collagen-I hydrogels
Hydrogels were composed of calf skin derived collagen-I (product 150026,
MP Biomedicals, Solon, OH) resuspended in 0.02 N acetic acid at
3 mg/mL. Collagen-I solution was combined with neutralizing solution
(0.52M sodium bicarbonate, 0.4 MHEPES, and 0.08 N sodium hydroxide),
cellular suspension media (DMEM þ 5% BSA for blocking) with or
without cells, and PEG-diNHS dissolved in dimethyl sulfoxide (DMSO;
100 mg/mL, product E3257, Sigma-Aldrich) or DMSO control. The ratio
for gel formation was 615: 308: 77: 4 for collagen-I: suspension media:
neutralizing solution: PEG-diNHS/DMSO. Experimental cell culture hy-
drogels were formed as 100 mL drops in 10 cm cell culture dishes in groups
of nine and maintained in 10 mL media. Hydrogels were released from
dishes using a spatula and dishes were maintained on an orbital shaker to
ensure gels did not settle and reattach to dish. Hydrogels were formed
with an initial cell concentration of 100,000 cells/mL of hydrogel.Rheology
Rheological measurements were performed on an AR-G2 rheometer (TA
Instruments, New Castle, DE). Hydrogels were formed in situ using
1 mL of hydrogel solution added between a 20 mm plate geometry and
the rheometer base at 15C, warmed to 37C, and allowed to gel for
15 min. For experimental cell culture hydrogels that cannot be formed
in situ on the rheometer and compacted during the 3 day time course, hydro-
gel dimensions were measured with the hydrogel constrained between par-
allel plates, using an 8 mm plate geometry, and plate diameter was set in the
software (Rheology Advantage, TA Instruments) to that of the constrained
hydrogel diameter. Consultation with the manufacturer (TA Instruments)
validated this method. Three 1 ml hydrogels each from a minimum of
two independent batches for cell independent, three 1 ml hydrogels each
from two independent batches for cell laden, and three 100 ml hydrogels
each from three independent batches for day 3 samples were characterized.
Hydrogel shear modulus was measured at 1 Hz, 0.1% strain at 37C.
Young’s modulus (E) was calculated from the software recorded shear
moduli (G0) using the formula [E ¼ 2 G0 (1 þ v)] with Poisson’s
ratio (v) assumed at 0.1 as reported in the literature (43). Cell containing
hydrogel moduli were obtained from gels with an initial seeding of
~200,000 cells/mL hydrogel.Microscopy
Fluorescent and phase contrast images of live or fixed cells were taken
with an inverted microscope (DMI 4000B Inverted Microscope, LEICA
Fibroblast Activation in the TME 251Microsystems, Buffalo Grove, IL), with a 10 objective (N PLAN 10X/0.25
PH 1,N/-/B, LEICAMicrosystems) or 40 objective (HCX FL FLUOTAR
40X/0.60 CORR PH 2,N/0-2/C, LEICA Microsystems) at room tempera-
ture utilizing an ORCA-ER digital camera (model C4742-95, Hamamatsu
Photonics, Bridgewater, NJ) and Volocity imaging software (Improvision/
PerkinElmer, Wlatham, MA). Images of live cells were acquired through
culture dishes with hydrogels in PBS whereas images of fixed cells were ac-
quired with hydrogels on cover slips in no medium.Viability assessment
Hydrogels were prepared as above. For live/dead assessment, hydrogels
were treated with propidium iodide at 10 mg/mL and Hoechst 33342 at
1 mg/mL for 5 min and imaged as described above. Cells were manually
counted from images. Cells with propidium iodide staining were counted
as dead and live cells were calculated from the total Hoechst stained pop-
ulation minus the propidium iodide population. For apoptosis and prolifer-
ation assessment, hydrogels were grown for 3 days and probed with
antibodies to Annexin V and Ki-67 as described below.Gel compaction assay
Hydrogels were prepared as above and imaged daily with an 8-megapixel
digital camera (XT894, Motorola, Schaumburg, IL). Gel images were
measured using Fiji (ImageJ) software (44), normalizing to a known standard
cell culture dish size. Hydrogels were imaged on day 0without media and on
day 3 in the presence of media.Media causes a slight distortion resulting in a
15% decrease inmeasured size, therefore datawas normalized to reflect this.Quantitative PCR
Hydrogels were prepared as above and cultured for 3 days. To collect cells,
9 hydrogels (one experimental replicate) were treated with collagenase
(product 02195109, MP Biomedicals) at 10 mg/mL until gels were digested
(30 to 60 min) at 37C on an orbital shaker. Cells were pelleted at 1000 xg
for 5 min, collagenase/media supernatant was aspirated, and cell pellets
were frozen at -80C for later analysis. mRNAwas purified from cell pellets
according to manufacturer’s methods with QIAshredder and RNeasy kits
(products 79654 and 74104, QIAGEN, Valencia, CA) with the addition
of DNase (product AM2222, Invitrogen/Life Technologies, Grand Island,
NY) to ensure RNA purity. qRT-PCR was carried out for 55 cycles
(95C/15s, 58C/15s, 72C/30s) using QuantiFast SYBR Green RT-PCR
Kit (product 204154, QIAGEN) on a Roche LightCycler 480 (Roche
Applied Science, Indianpolis, IN). qPCR primers are listed in Table S2 in
the Supporting Material, Palladin primers were designed to detect isoforms
1, 3, and 4; base pair No. 2347–2435. Expression fold change values were
calculated using the 2-DDCt method as described by Livak and Schmittgen
(45). The density of fibroblasts per milliliter of hydrogel had no impact on
gene expression, assessed in PEG hydrogels (Fig. S1 C). Reported values
for Figs. 3 and 4 are normalized to RSM day 0 condition, all other figures
are normalized to their respective 3D collagen-I cell embedded hydrogel
(COL) day 3 values. For all drug treatment conditions (see Figs. 5, 6, and
S3), three experimental replicates were combined before RNA purification
because of low RNA yields and six technical replicates were completed.Immunocytochemistry
Hydrogels were prepared as above and cultured for 3 days. Gels were fixed
with 4% paraformaldehyde solution for 45 min at 37C, permeabilized with
0.25% Triton-X solution for 45 min at room temperature except in the case
of Annexin V, washed with PBS þ 0.05% sodium azide (PBS-NaN3), and
incubated for 2 h at room temperature or overnight at 4C in blocking so-
lution (5% goat serum, 1% BSA, 0.05% NaN3 in PBS). Samples were thenincubated for 24 h with primary antibodies as indicated (a-SMA @ 1:200,
product MA1-37027, Thermo Scientific; FN-EDA@ 1:500, product F6140,
Sigma-Aldrich; TGFb @ 1:500, product MA5-15065, Thermo Scientific;
Palladin @ 1:200 (polyclonal antibody detects isoforms 1, 3, & 4; amino
acids No. 725–740), product A3986, Sigma-Aldrich; a-tubulin @ 1:400,
product ATN02, Cytoskeleton (Denver, CO); FAK @ 1:100, MAB-2156/
05-1139, EMDMillipore, Ki-67 @ 1:100, product 550609, BD Biosciences
(San jose, CA); Annexin V @ 1:500, product PA5-27872, Thermo Scienti-
fic) followed by three 60 min washes with PBS-NaN3. Samples were then
incubated for 24 h with secondary antibodies (@ 1:300, Alexa Fluor, Life
Technologies, Grand Island, NY), and/or rhodamine phalloidin for f-actin
(product P1951, Sigma-Aldrich) and counterstained with 4’,6-diamidino-
2-phenylindole, followed by three 60 min washes with PBS-NaN3.
Immunostained hydrogels were moved to eight-chamber cell culture slides
(product 154534, Thermo Scientific) with 100 mL PBS-NaN3 for storage.
Excess PBS-NaN3 was aspirated before imaging of hydrogel to reduce light
scattering. All hydrogels for multiple trials were stained and imaged
concurrently with single dilutions of antibodies and exposure times were
held constant for each antibody.Semi-quantitative immunocytochemistry
calculations
ImageJ was utilized for protein quantification (see Figs. 3 C and 4 D) (44).
Cells were identified utilizing actin staining by threshold (triangle, auto) to
define cell boundaries and measure cell area. Expression levels of marker
proteins were measured from the integrated intensity of fluorescent signal
from within, or outside of (FN-EDA), the identified fibroblast areas and
normalized for the cell, or noncell, area. Intensity was further corrected
for background fluorescence by subtracting the average intensity from hy-
drogels without cells. The intensity values were averaged and all values
were normalized to COL RSM values. Hydrogel types displayed no differ-
ence in background fluorescence intensity (data not shown).
CellProfiler (46,47) was utilized to quantify palladin localization. Nuclei
(primary objects) were identified utilizing 4’,6-diamidino-2-phenylindole
staining to define nuclear boundaries (adaptive threshold, robust back-
ground threshold method) and cells (secondary objects) were identified
by f-actin staining (propagation identification, adaptive threshold, back-
ground threshold method). Cytoplasm was identified as cell area minus
nuclear area (tertiary objects). The integrated intensity for each nucleus
identified was set as a ratio to the cytoplasmic intensity for the cell (nu-
cleus/cytoplasm).Cellular morphology assessment
Hydrogels were prepared as above and immunostained with rhodamine
phalloidin for f-actin (product P1951, Sigma-Aldrich). The number of
cellular projections was counted manually; cell length and width was
measured manually using Volocity software (Improvision/PerkinElmer) to
calculate cell aspect ratio.Cytokine identification
Cytokines present in fibroblast conditioned media were identified using
a semi-quantitative, sandwich-based, human cytokine antibody array
(product AAH-CYT-1000, RayBiotech, Norcross, GA) and quantified using
Fiji (ImageJ) software and normalized to included controls (44). Only one
experimental replicate was completed.Signaling manipulations
Function blocking antibodies to b1 integrin (product 555002, BD Biosci-
ences) were used at 10 mg/ml and to b3 integrin (product 554951, BDBiophysical Journal 109(2) 249–264
252 McLane and LigonBiosciences) were used at 5 mg/ml. Inhibitors of FAK (product 3414, FAK
Inhibitor 14, Tocris Bioscience, Bristol, UK), Phosphoinositide 3-Kinase
(PI3K) (product 1130, LY 294002, Tocris) and CCR4 (product 227013,
CAS 864289-85-0, EMD Millipore, Temecula, CA) were used at 4 uM,
5 uM, and 400 nM, respectively. Recombinant human chemokines CCL2/
MCP-1, CCL5/RANTES, CCL17/TARC, CCL22/MDC, and CCL3L1/
MIP-1a were purchased from R&D Systems (Minneapolis, MN) (products
279-MC-010, 278-RN-010, 364-DN-025, 336-MD-025, 509-MI-025) and
were used at the manufacturer’s recommended concentrations as a mixed
cocktail at 10 ng/ml each CCL. Human plasma fibronectin (product CB-
40008, Fisher Scientific, Logan, UT) was used at 50 mg/ml. TGFb (product
PHG9204, Invitrogen) was used at 25 ng/mL.Statistical analysis
Statistical analysis was performed using Microsoft Excel with the Real Sta-
tistics Resource Pack (Release 2.14.1, http://www.real-statistics.com/).FIGURE 1 Collagen-I hydrogel stiffness can be tuned with PEG-diNHS
cross-linking. (A) Collagen-I gels form by physical cross-linking be-
tween fibers. Hydrogel stiffness can be increased by introducing more rigid
cross-links between collagen-I and PEG-diNHS. (B) Stiffness of collagen-I
(COL) and collagen-I PEG-diNHS hydrogels (PEG) without cells was
measured by rheometry. Young’s modulus was 209.6 Pa 5 4.8 for soft
COL gels (n ¼ 6) and 770.5 Pa5 22.3 for stiff PEG gels (n ¼ 12), corre-
sponding to values reported for normal and tumor adjacent stroma (1,2).
Diamonds in the box and whisker plots represent the mean, and the midline
is the 50th percentile. The top and bottom bar represent the 90th and 10th
percentile, respectively, and the top and bottom boxes represent the 75th
and 25th percentile, respectively. (C) Stiffness of hydrogels with encapsu-
lated cells. The elastic modulus of COL gels with cells was 289.2 Pa5 12.7
(n ¼ 6) and of PEG gels with cells was 769.0 Pa 5 35.7 (n ¼ 6).
(D) Stiffness of hydrogels over time. Hydrogels with encapsulated cells
were cultured for 3 days. Elastic modulus of COL gels at day 3 was
262.0 Pa 5 20.0 (n ¼ 9) and of PEG gels at day 3 was 716.8 Pa 5 44.6
(n¼ 9). All Young’s modulus values were obtained by converting measured
bulk modulus with the formula E ¼ 2G(1 þ v), with v as 0.1 (43). Asterisk
indicates significant difference. Student’s t-test p values < 0.05. Error bars
show standard error of the mean. To see this figure in color, go online.RESULTS
Biomimetic hydrogels to model the tumor
microenvironment
Although tumors are often 10- to 20-fold stiffer than normal
tissue, the stroma surrounding solid tumors is only three- to
fivefold stiffer than normal stroma (1,2). We sought to
model this more subtle change in TME stiffness with 3D
collagen-I hydrogels stiffened with a short bio-inert
polyethylene glycol polymer cross-linker (stiffened versus
unstiffened, PEG and COL respectively, Fig. 1 A). This
PEG-diNHS cross-linking mimics collagen-I cross-linking
in vivo, creating a more rigid ECM mesh without changing
the concentration of collagen ligand (23). Our goal was to
generate soft hydrogels (~200 Pa) and stiffened hydrogels
(~800 Pa) that recapitulate the mechanical environments
found in normal tissue and in the tumor microenvironment
(1,2). To determine the bulk stiffness of our hydrogels, we
performed rheology on hydrogels without cells and on hy-
drogels with cells at day 0 and day 3. The stiffness of hydro-
gels without embedded cells was 209.6 Pa5 4.8 (COL) and
770.5 Pa5 22.3 (PEG) (Fig. 1 B). The addition of cells led
to a slight increase in stiffness of the soft hydrogels
(289.2 Pa 5 12.7) but did not change the stiffness of the
cross-linked hydrogels (769.0 Pa 5 35.7) (Fig. 1 C). In
addition, the stiffness of the gels remained constant over
the experimental time course (Fig. 1 D). These results indi-
cate that we can create a controlled environment in which
stiffness is precisely tunable and can be maintained during
the experimental time course.Fibroblasts are activated to myofibroblasts by
tumor-associated stiffness
To determine if the increased stiffness found in the TME is
sufficient to lead to fibroblast activation, we grew human fi-
broblasts in soft collagen-I hydrogels (COL) and in stiffened
PEG-diNHS cross-linked collagen-I hydrogels (PEG) forBiophysical Journal 109(2) 249–2643 days. Hydrogel cross-linking had no effect on cell
viability, proliferation, or apoptosis (Fig. S1, A and B). Sec-
ond-harmonic generation microscopy showed that the cells
can organize the collagen matrix in both COL and PEG hy-
drogels (Fig. 2 A). At day 0, COL and PEG matrices are
similar with short, randomly oriented collagen-I fibers, but
by day 3 the matrix collagen has been rearranged into
long, directional bundles in both conditions. We quantified
FIGURE 2 Hydrogel structure and compaction. (A) Representative sec-
ond harmonic generation images of collagen-I organization in soft (COL)
or stiff (PEG) hydrogels. Scale bar: 50 mm. (B) Quantification of skewness
from second-harmonic generation images, normalized with collagen day 0
and 50% percentile at 0. Forty-two images from each gel were quantified,
with six gels per condition. Skewness decreases as fibril organization in-
creases (48). Box and whisker plots as in Fig. 1 B. Asterisk indicates
significant difference from day 0. Student’s t-test p values < 0.0001.
(C) Hydrogel compaction over 3 days, CM (COL n ¼ 41; PEG n ¼ 39).
Asterisk indicates significant difference from day 0. Student’s t-test
p values < 0.005. Error bars show standard error of the mean.
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ness. Skewness is a measure of the imbalance of the distri-
bution of a variable about its mean, in this case pixels that
are darker or brighter than the image mean. Images with
greater organization, such as those with large fibrils, exhibit
a left-tailed shift in the distribution that is calculated as a
negative shift in skewness (48). Both hydrogel types show
a significant negative shift in skewness from day 0 to
day 3, suggesting that the matrices are being organized by
the embedded cells (Fig. 2 B). Compaction of a hydrogel
is an additional measure of the reorganization and contrac-
tion of the matrix by embedded cells. We observed signifi-
cant decreases in hydrogel area between day 0 and day 3
in both COL and PEG gels, but these were more pronounced
in PEG hydrogels (Fig. 2 C), indicating that cells can
compact both gels, but do so more effectively in the stiff-
ened matrix. Together, these results suggest that fibroblasts
embedded in both soft and stiffened hydrogels can reorga-
nize and compact the matrix, but that they do so more effi-
ciently in the stiffer matrix representative of the TME.
Next we assessed fibroblast activation in soft and stiff-
ened matrices by looking at morphology and patterns of
gene expression. Fibroblasts cultured in both soft and stiff
3D matrices adopt an elongated spindle-like morphology
with prominent stress fibers (Fig. 3 A). Cells grown in
the stiffened gel had a significantly higher aspect ratio
and fewer projections than those grown in the soft gel
(Fig. 3 B). An exaggerated spindle-like morphology is indic-
ative of myofibroblast-like activation, and these data indi-
cate that cells in stiffer gels show a more activated
phenotype than those in the soft gels.
We then measured the relative expression of markers of
fibroblast activation by semi-quantitative immunocyto-
chemistry, as it was difficult to obtain sufficient material
for Western blots from these small gels. Cells grown in stiff
gels had higher protein levels of a-smooth muscle actin
(a-SMA), palladin, and FN-EDA than cells grown in soft
gels (Fig. 3 C). Extracellular FN-EDA was also increased,
indicating an increase in fibronectin deposition as would
be expected by activated fibroblasts. TGFb expression, on
the other hand, was unchanged, suggesting that the TGFb
autocrine loop seen with long-term tumor:stroma interaction
was not activated in 3 days by growth in stiffened gels (49).
We also assessed mRNA expression of aSMA, palladin,
FN-EDA, fibroblast activation protein (FAPa), and TGFb
by qRT-PCR. We extracted RNA from cells grown in both
COL and PEG hydrogels, as well as from cells grown in
2D on collagen-I coated plates to determine the effect of
growth in 3D versus 2D. The expression of all markers
was increased when cells were grown in 3D hydrogels in
comparison with growth in 2D (Fig. S2 A), and the levels
of all markers except TGFb were further increased when
cells were grown in stiff gels versus soft gels, consistent
with the observed protein expression (Fig. 3, C and D).
The expression pattern seen in the stiff PEG hydrogels isBiophysical Journal 109(2) 249–264
FIGURE 3 ECM stiffness representative of the tumor microenvironment can lead to fibroblast activation. (A) Representative images of fibroblasts in soft
(collagen-I) or stiff (collagen-I PEG-diNHS) hydrogels (stained with phalloidin to label f-actin). Scale bar: 20 mm. (B) Quantification of the number of pro-
jections from the cell body and cell aspect ratio (COL n ¼ 12; PEG n ¼ 11). (C) Semi-quantitative immunocytochemistry of aSMA, palladin, intracellular
FN-EDA, TGFb, and extracellular FN-EDA. All values were normalized to cells in RSM COL (n¼ 3). Asterisk indicates significant difference between soft
and stiff gels. (D) qRT-PCR of markers of fibroblast activation. All levels were normalized to expression levels in cells in collagen-I hydrogels in complete
media (n ¼ 3). Asterisk indicates significant difference between cells in soft COL gels and in stiff PEG gels, Student’s t-test values < 0.05. Error bars show
standard error of the mean. To see this figure in color, go online.
254 McLane and Ligonalso similar to that seen when fibroblasts are directly acti-
vated by TGFb treatment (Fig. S2 B). Together, these results
suggest that growth in a stiffened collagen-I environment
(800 Pa) with mechanical properties similar to the TME is
sufficient to convert fibroblasts to a myofibroblast-like state.
Further, they indicate that we can use this pattern of gene
expression (increases in aSMA, palladin, FAPa, and FN-
EDA (Fig. 3 D)) as a measure of this stiffness-induced fibro-
blast activation.Serum factors can alter activation response
Chemical signals as well as mechanical signals are known to
play a role in the activation of fibroblasts. To determine if an
increase in stiffness is sufficient to activate fibroblasts in the
absence of chemical cues, we investigated the response of
fibroblasts to stiffness under serum depletion conditions.
Fibroblasts were cultured in RSM (1% serum) and then
embedded in either soft or stiff gels with RSM. Growth in
RSM did not affect cell viability (Fig. S1). Fibroblasts
grown in RSM had a more stellate morphology than those
grown in complete media (CM). Cells grown in both soft
and stiff gels had multiple cellular protrusions and few stressBiophysical Journal 109(2) 249–264fibers (Fig. 4 A). The number of projections was higher than
in cells grown in CM, but there was no difference between
cells grown in soft or stiff gels in RSM (Fig. 4 B). The aspect
ratio was also decreased in both soft and stiff gels to the
baseline level seen in soft gels in CM (Figs. 3 B and 4 B).
In addition, cells grown in RSM were significantly less
able to compact the hydrogel than were those grown in
CM, although cells in stiff gels in RSM did show a slight in-
crease in compaction over those in soft gels (Fig. 4 C).
These data suggest that although cells grown in RSM in stiff
gels are slightly more activated than those grown in soft gels
in RSM, and, in both cases, they are much less activated
than those grown in CM.
The expression of proteins associated with fibroblast acti-
vation was also reduced in cells grown in RSM in compar-
ison with CM (Fig. 4 D). aSMA and palladin showed a
slight stiffness dependent increase in expression, although
it was much smaller than that seen in CM, and FN-EDA
expression was unaffected by the increase in stiffness.
TGFb expression was not affected by stiffness or serum
reduction. These changes in protein expression were
mirrored in mRNA levels. All transcripts were greatly
decreased in comparison with CM except TGFb, which
FIGURE 4 Depletion of soluble growth factors blocks fibroblast activation. (A) Representative images of fibroblasts grown in soft (collagen-I) or stiff
(collagen-I PEG-diNHS) hydrogels with reduced serum media (RSM) (stained with phalloidin to label f-actin). Scale bar: 20 mm. (B) Quantification of
the number of projections from the cell body and cell aspect ratio (COL n ¼ 8; PEG n ¼ 7). (C) Hydrogel compaction in reduced serum media (COL
n ¼ 69; PEG n ¼ 61). Asterisk indicates significant difference. Student’s t-test p values < 0.005. (D) Semi-quantitative immunocytochemistry for
aSMA, palladin, FN-EDA, TGFb, and extracellular FN-EDA comparing cells grown in CM with those grown in RSM in soft (COL) or stiff (PEG) gels
(n ¼ 3). (E) qRT-PCR for markers of fibroblast activation comparing cells grown in CM with those grown in RSM (n ¼ 3). Asterisk indicates significant
difference between COL and PEG conditions. Hash represents significant difference between RSM and CM conditions. Student’s t-test values < 0.05. Error
bars show standard error of the mean. To see this figure in color, go online.
Fibroblast Activation in the TME 255remained constant (Fig. 4 E). aSMA, palladin, and FAPa all
showed small stiffness dependent increases in transcript
level, as did FN-EDA, even though it did not show an in-
crease in protein level (Fig. 4 E). Together these data sug-
gest that mechanical stiffness alone is not sufficient to
result in strong fibroblast activation, but that soluble factors
found in serum are also required.Both CCL growth factors and serum fibronectin
are necessary for focal adhesion clustering
To explore the link between soluble factors found in serum
andmechanical signaling, we first tested whether focal adhe-
sion clustering was affected by serum concentration. Growth
factor receptors have been shown to directly interact with in-
tegrins and both integrin and growth factor receptor signaling
are modified by these interactions (50). Furthermore, integ-
rins and growth factor receptors have been shown to coclus-
ter at focal adhesions and recruit FAK to the adhesion sites
(50). To determine if growth factors present in serummay ac-
count for the differences we observed in fibroblast activation
between RSM and CM, we looked at FAK localization and
clustering. When cells were grown in CM, clusters of FAK
labeling were seen, but when cells were grown in RSM,
FAK labeling was dispersed (Fig. 5 A). To quantify thisloss of clustering, we calculated the mean standard deviation
of FAK intensity for each condition and saw a decrease in
variation from CM to RSM in both COL and PEG, suggest-
ing that FAK clustering occurs in the presence of serum, but
not in low serum conditions (Fig. 5 G).
There are many growth factors present in serum. We
screened our culture media for 120 chemokines and found
that prominent among them were the CCLs (Table S1).
We then screened the fibroblasts for all 10 known CCL re-
ceptors and found that only CCR4 is expressed in these cells
(Table S2). Pharmacological inhibition of CCR4 in cells
grown in CM resulted in the same dispersed FAK signal
(Fig. 5 B) and lack of clustering (Fig. 5 G) as seen in
RSM conditions. In addition, mRNA expression of genes
associated with fibroblast activation was also significantly
decreased with CCR4 inhibition (Fig. 5 D). However, intro-
duction of a cocktail of recombinant CCR4 ligands into
RSM (CCLs 2, 4, 5, 17, and 22) (51,52), did not rescue
FAK clustering (Fig. 5, B and G) or changes in mRNA
expression (Fig. 5 E), suggesting that CCL signaling alone
is not sufficient to induce receptor clustering and allow
the cell to respond to mechanical inputs.
Fibronectin has also previously been shown to play a
role in fibroblast activation (53,54), so we tested whether
addition of fibronectin alone to RSM could rescue FAKBiophysical Journal 109(2) 249–264
FIGURE 5 Both serum CCL growth factors and fibronectin are necessary for FAK clustering and fibroblast activation. (A) Cells grown in complete media
(10% serum) show punctate clusters of FAK, whereas FAK labeling is diffuse in cells grown in reduced serum media (1% serum). (B) Inhibition of CCR4
receptor with a CCR4 antagonist drug in CM blocks FAK clustering. Reintroduction of a cocktail of recombinant CCL growth factors does not rescue FAK
clustering in RSM conditions. (C) Fibronectin addition to RSM does not rescue FAK clustering, but addition of fibronectin and CCLs together in RSM con-
dition does recover punctate FAK staining. Scale bar: 20 mm. (D) qRT-PCR of markers of fibroblast activation in cells treated with CCR4 receptor antagonist
in CM (n ¼ 3). Expression level of each marker is seen in RSM conditions shown with diamond markers for comparison. (E) qRT-PCR of markers of fibro-
blast activation in cells in RSM hydrogels supplemented with recombinant CCL growth factors (n ¼ 3). (F) qRT-PCR of markers of fibroblast activation in
cells in RSM hydrogels supplemented with fibronectin (n¼ 3). Asterisk indicates significant difference from control. Student’s t-test values< 0.05. All qPCR
data normalized to COL condition. (G) Mean standard deviation of FAK staining intensity in COL and PEG hydrogels (n ¼ 5). Images with bright and dark
spots (clusters and unlabeled background) have higher standard deviation than those with more uniform labeling. Asterisk indicates significant difference
from CM. ANOVA p-values < 0.05. Error bars are standard error of the mean. (H) qRT-PCR of markers of fibroblast activation in cells grown in RSM
supplemented with both human serum fibronectin and CCL cocktail (n ¼ 3). Asterisk indicates significant difference from RSM control. Student’s t-test
values < 0.05. Error bars show standard error of the mean. To see this figure in color, go online.
256 McLane and Ligonclustering and fibroblast activation, but we did not see a
rescue of FAK clustering (Fig. 5 C), or fibroblast activation
(Fig. 5 F) with the addition of fibronectin alone. We then
added a combination of fibronectin and the CCL cocktail,
and we observed a significant rescue of FAK clustering
(Fig. 5, C andG). Analysis of the pattern of gene expression,
however, suggests that the combination of fibronectin and
CCLs at the concentrations supplied only partially rescues
fibroblast activation, as FN-EDA and palladin showed little
or no response to this combination (Fig. 5 H). In addition,
hydrogel compaction was also not completely rescued by
the addition of these serum factors (data not shown). Taken
together, these data indicate that both CCL growth factors
and their cognate CCR4 receptors, as well as serum fibro-Biophysical Journal 109(2) 249–264nectin, are key for FAK clustering, which is necessary for
cells to respond to mechanical cues and for myofibroblast
activation. However, other serum factors may play a role
in more complete activation or a different concentration of
specific CCLs or fibronectin may be important, as some
markers of activation showed little or no response and hy-
drogel compaction was not completely rescued, despite
the recovery of FAK clustering.Fibroblast activation is regulated by b1 and b3
integrins, FAK, and PI3K
Next we probed the outside-in signaling pathways to deter-
mine how the mechanical signaling from increased stiffness
Fibroblast Activation in the TME 257leads to fibroblast activation. Cells typically adhere to the
ECM via integrins, so we first used blocking antibodies
that interfere with the interaction between integrins and their
ligands. We treated cells with antibodies to either integrin
b1 to block collagen-I binding integrins (which all include
the b1 subunit), or integrin b3 that binds fibronectin and
other RGD containing ECM proteins (55,56). The effects
of these blocking antibodies on fibroblast activation were
complex. Blocking b1 integrin in stiff gels led to increases
in the expression of FAPa, and FN-EDA and a decrease in
palladin expression (Fig. 6 A), and blocking b3 integrin
led to small decreases in aSMA and FAPa expression and
an increase in palladin expression (Fig. 6 B). Both anti-
bodies had overall smaller effects when added to cells in
soft gels except that blocking b3 integrin led to an enhanced
increase in palladin expression (Fig S3), suggesting that the
effects observed in stiff gels were attributable primarily to
interfering with mechanical sensing. Blocking b1 integrin
led to a modest increase in TGFb expression in both soft
and stiff gels and blocking b3 integrin had no effect on
TGFb expression in either gel, suggesting that TGFb is
not sensitive to mechanical inputs. To interpret these data,
we calculated the effect of these treatments on stiffness-
induced activation by comparing the expression pattern in
stiff gels with and without inhibitors (Table 1). Blocking
b1 integrin had a paradoxical effect—it did not block stiff-
ness-induced activation as expected, but rather partially
enhanced the activation (Fig. 6 A and Table 1). Blocking
b3 integrin, on the other hand, did partially block stiff-
ness-induced activation (Fig. 6 B and Table 1). Interestingly,the effect on palladin expression was opposite that of other
indicators of fibroblast activation—it was decreased by b1
inhibition and increased by b3 inhibition. Together, these
data suggest that integrins have complex roles in activation
and perhaps have regulatory functions.
We then tested whether inhibition of FAK could block
stiffness-induced fibroblast activation. FAK is found at
adhesions made by both b1 and b3 integrins and we also
saw that FAK clustering is correlated with fibroblast activa-
tion. Pharmacological inhibition of FAK in stiff gels signif-
icantly blocked stiffness-induced activation, resulting in
lower expression of all markers of activation except FN-
EDA (Fig. 6 C and Table 1). The effect of FAK inhibition
in soft gels was minimal and did not alter aSMA or palladin
expression (Fig S3), suggesting that FAK is central in the
modulation of stiffness sensing in stiffness-induced fibro-
blast activation. Phosphatidylinositide 3-kinase (PI3K) is
downstream of FAK and known to play a role in transducing
mechanical signals (57). Therefore we tested whether inhi-
bition of PI3K could block stiffness-induced fibroblast acti-
vation. Pharmacological inhibition of PI3K in stiff gels
partially blocked stiffness-induced activation, resulting in
significantly reduced expression of aSMA and FAPa, but
no change in the expression of FN-EDA or palladin
(Fig. 6 D and Table 1). The effect of PI3K inhibition in
soft gels was minimal (Fig S3), suggesting that the effects
seen in stiff gels were because of interfering with mechano-
signal transduction.
We then wanted to test whether all FAK signaling in stiff-
ness-induced fibroblast activation was being transmittedFIGURE 6 b1 and b3 integrins, FAK, and PI3K
all play roles in control of fibroblast activation in
stiff hydrogels. (A) b1 integrin activity was in-
hibited with a blocking antibody and the expression
of markers of fibroblast activation was measured by
qRT-PCR (n ¼ 3). (B) b3 integrin activity was in-
hibited with a blocking antibody and the expression
of markers of fibroblast activation was measured by
qRT-PCR (n¼ 3). (C) Focal adhesion kinase (FAK)
activity was blocked with FAK Inhibitor 14 drug
and the expression of markers of fibroblast activa-
tion was measured by qRT-PCR (n ¼ 3). (D) Phos-
phoinositide 3-kinase (PI3K) activity was inhibited
with LY 294002 and the expression of markers of
fibroblast activation was measured by qRT-PCR
(n ¼ 3). (E) Cells were treated with a combination
of FAK and PI3K inhibitors and the expression of
markers of fibroblast activation was measured by
qRT-PCR (n ¼ 3). (F) Cells were treated with a
combination of b1 integrin blocking antibody and
PI3K inhibitor and the expression of markers of
fibroblast activation was measured by qRT-PCR
(n ¼ 3). Asterisk indicates significantly different
increase. Hash indicates significantly different
decrease. All data is normalized to COL control.
Student’s t-test values< 0.05. All error bars signify
standard error of the mean.
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TABLE 1 Quantification of changes in transcription of













b1 integrin antibody 23 396 186 79 218
b3 integrin antibody 75 64 3 149 2
FAK inhibitor 103 128 4 75 40
PI3K inhibitor 48 78 -38 5 5
FAK and PI3K inhibitors 61 81 20 417 32
b1 antibody and PI3K
inhibitor
62 72 193 17 192
Values are reported as percent change from level of untreated stiff hydrogel.
Statistically significant changes are in bold. n ¼ 3.
258 McLane and Ligonthrough PI3K, so we added pharmacological inhibitors of
both FAK and PI3K to cells in stiff gels. If all FAK signaling
goes through PI3K, then the addition of both inhibitors
should mimic that of either alone. For aSMA, FAPa, and
FN-EDA the effect was the same with both inhibitors
together or either alone (Fig. 6 E). But the effect on palladin
was strikingly different. FAK inhibition caused a decrease in
palladin expression, whereas PI3K inhibition had no effect
on palladin. But when both FAK and PI3K were inhibited,
palladin expression was significantly higher (Fig. 6, C–E).
Similarly, we sought to determine if all effects of blocking
b1 integrin signaling are mediated by PI3K, so we treated
cells with a combination of PI3K inhibition and b1 blocking
antibodies. We observed decreases in aSMA and FAPa
expression, similar to that seen with PI3K inhibition alone,
and increases in FN-EDA and TGFb expression similar to
that seen with blocking b1 integrin alone (Fig. 6 F). Taken
together this data suggests that FAK signaling is transmitted
through PI3K for aSMA and FAPa transcription, that FAK
signaling for aSMA and FAPa is dependent on interactions
between b1 and b3 integrins, that FN-EDA and TGFb are
regulated by b1 integrin–related signaling, and that FAK
and PI3K have a complex regulatory relationship involving
both integrin b1 and b3 in palladin transcription.FIGURE 7 Palladin localization is controlled by integrins. (A) Palladin
localized to the nucleus when b1 integrin was blocked and localized to
the cytoplasm when b3 integrin was blocked (n ¼ 3). (B) Quantification
of the change in localization relative to the amount present in controls.
Asterisk indicates significant difference from control. Student’s t-test
values< 0.005. All error bars signify standard error of the mean. (C) Repre-
sentative images of palladin nuclear localization.Palladin localization is controlled by matrix
adhesions
We observed a curious pattern of palladin gene expression
when we blocked b1 or b3 integrins that was opposite that
of other myofibroblast associated genes (Fig. 6, A and B).
Palladin has been shown to play a role in the regulation of
myofibroblast associated gene expression (12,38,39), in
addition to its more established actin-associated roles
(33–37). Palladin has also been shown to localize to the nu-
cleus in some cell types (40,41), which is consistent with a
role in transcriptional regulation. We hypothesized that the
balance of palladin localization between cytoplasmic/
actin-associated and nuclear may regulate palladin func-
tion in these cells, and further that this balance may be regu-
lated by the mechanotransduction pathways. Therefore, weBiophysical Journal 109(2) 249–264probed for the localization of palladin while manipulating
integrin-matrix interactions. Blocking b1 integrins in stiff
hydrogels led to an accumulation of palladin in the nucleus
(30% increase over control) whereas blocking b3 integrins
led to an exclusion of palladin from the nucleus (18%
decrease over control) (Fig. 7), with a similar effect in
soft hydrogels (Fig. S4). These data suggest that palladin
localization is controlled by an integrin-mediated pathway,
which may then control the balance between the function
of palladin as a transcriptional regulator and actin-associ-
ated protein.DISCUSSION
It has been hypothesized that the elevated stiffness of the
stroma surrounding tumors contributes to the transformation
of stromal cells into the tumor associated phenotypes seen
Fibroblast Activation in the TME 259in vivo (58–60). In this study, we demonstrate that we can
make a collagen-I based, stroma-mimetic, 3D hydrogel sys-
tem in which we can precisely tune mechanical stiffness
within the physiologically relevant range. We then used
this system to show that fibroblasts are activated to a myofi-
broblast-like state with a physiologically relevant increase
in stiffness alone. We then investigated the interconnected
roles of stiffness, soluble factors such as fibronectin and
chemokines, and signaling through integrin receptors upon
this activation. We found that fibroblasts acquire a myofi-
broblast-like phenotype when cultured in collagen-I 3D hy-
drogels with a stiffness that mimics the tumor-associated
stroma. Although others have shown that increased stiffness
plays a role in fibroblast activation, these experiments were
performed with models in which the stiffness was unknown
or increased 10-fold or more greater than normal stroma
(4,15,61). In this study we have shown that a fourfold in-
crease in stiffness, which is more physiologically appro-
priate, is sufficient to lead to fibroblast activation. The
activation induced by increased stiffness was similar to
that seen with TGFb treatment in the soft COL hydrogels
(Fig. S2 B). The transition from 2D culture to 3D also
had a significant effect. Cells grown in 2D culture on
collagen-I–coated surfaces had a more senescent phenotype
(Fig. S2 A); this could be attributable either to the change in
geometry or the fact that 2D substrate (tissue culture plastic)
is orders of magnitude stiffer than the 3D hydrogels.
We also found that serum factors are necessary for the
stiffness-induced activation we observed, and that CCLs
and fibronectin, in particular, are important in this process
(Fig. 4). Other soluble factors may play a role as well, as
the CCLs and fibronectin do not completely rescue the
effect. Other stromal ECM components such as FN-EDA
that are deposited by the fibroblasts themselves may also
play a role in promoting fibroblast activation, as fibroblasts
do remodel the matrix over the experimental time course.
We found that FAK clustering is associated with myofi-
broblast activation and is controlled in part by the availabil-
ity of fibronectin. Fibronectin can be classified into two
subgroups, plasma and matrix, both of which have multiple
isoforms (62). The stiffness-induced activation we observed
was blocked in reduced serum conditions and partially
rescued with the addition of plasma fibronectin (Fig. 5).
Others have suggested that the matrix FN-EDA can lead
to fibroblast activation, but plasma fibronectin has also
been shown to alter fibroblast activity in a wound healing
model (53,63). Perhaps some fibronectin domains such as
FNIII10, which is conserved between plasma and matrix
FN and interacts with integrin avb3 (62), are necessary
for proper integrin engagement and clustering to allow for
activation, whereas other domains such as EDA actually
stimulate activation.
We also found that the CCR4 and its ligands, the CCLs,
are necessary for FAK clustering and fibroblast activation
as well. CCR4 is expressed by fibroblasts, and is upregu-lated in wounded tissue and correlated with wound healing,
suggesting that it may be associated with fibroblast activa-
tion (64). It has been suggested that the fibroblasts in the
tumor stroma behave like a wound that never heals
(65,66), and CCR4 signaling may play a part in this process.
Integrins and other growth factor receptors have also been
shown to cocluster, which is necessary for their downstream
signaling (50,67), and perhaps CCR4 and integrins cocluster
and coordinate downstream signaling through focal adhe-
sions as well.
Fibroblast activation is not a simple off/on switch. There
is a continuum between the two states, and many other
related states as well. We examined a range of indicators
of fibroblast activation, including morphology and the
expression of several genes at both the protein and mRNA
level. We found that there was an overall pattern of activa-
tion to a myofibroblast-like state when cells were grown
in the stiffened gels, but there were subtle differences in
gene expression between the various markers that may
elucidate their specific regulation. a-smooth muscle actin
(aSMA) is one of the most commonly employed markers
of the myofibroblast phenotype, and it is known to be
responsible for the generation of contractile force (68).
Expression of aSMAwas completely dependent on mechan-
ical stiffness, as no drug or antibody manipulation showed
an effect in soft COL (Fig. S3). aSMA expression is in-
hibited when FAK-PI3K signaling is blocked, suggesting
that it’s activated by FAK-PI3K signaling, consistent with
previous reports (69,70). We also found that blocking b3 in-
tegrin led to a decrease in aSMA expression, suggesting that
b3 integrins participate in the regulation of aSMA.
FAPa is a transmembrane serine protease that can
degrade collagen-I and has been cited as a marker of acti-
vated fibroblasts (71). We found that similar to aSMA,
FAPa is induced in a stiffness dependent manner, stimulated
through FAK-PI3K signaling, in agreement with previous
work (72), and regulated by signaling through b3 integrins.
Inhibition of FAPa has been shown to lead to a decrease in
aSMA expression as well, so it is possible that the aSMA
decrease we observed is also attributable in part to the inhi-
bition of FAPa (Fig. 6) (71). Somewhat surprisingly, block-
ing b1 integrins led to an increase in FAPa expression, in
agreement with a previous report also showed that blocking
b1 integrin-induced FAPa expression (73). These data sug-
gest that a balance of b1 and b3 integrin interactions control
fibroblast activation.
Although there were slight differences in the details, over-
all, the expression patterns of aSMA, FAPa, and FN-EDA
were similar. In contrast, the expression of palladin was
strikingly different. Our data show that palladin expression
is induced by stiffness like the other markers, but the regu-
lation is very different. Blocking b1 integrins leads to a
decrease in palladin expression and blocking b3 integrins
leads to an increase. Further, inhibiting FAK leads to a
decrease in palladin expression, but blocking PI3K has noBiophysical Journal 109(2) 249–264
260 McLane and Ligoneffect, and blocking both FAK and PI3K leads to a signifi-
cant increase in expression. Together, these results suggest
a complex control mechanism involving b1 integrins, b3 in-
tegrins, FAK, and PI3K signaling.
To explain the complex regulation of palladin and other
markers of activation suggested by our data, we propose a
model (Fig. 8) in which palladin expression and the expres-
sion of aSMA and FAPa can be explained by three points:
1) palladin expression is stimulated by stiffness through the
FAK-PI3K-Akt pathway; 2) palladin interactions with focal
adhesions and the actin cytoskeleton alter its ability to regu-
late the expression of other activation associated proteins;
and 3) the distribution of phosphoinositide 3-kinase
(PI3K) activity between FAK and other receptor tyrosine ki-
nases (RTK) alters palladin expression. We also propose that
FN-EDA and TGFb expression can be explained via a
mechanism requiring both FAK and palladin transcriptional
signaling.
Palladin expression has been shown to be stimulated
through the PI3K-Akt pathway in 2D (74), as well as by
FAK (75). aSMA and FAPa have also been shown to be
dependent on FAK-PI3K signaling (69,70,72). Palladin
has also been demonstrated to interact with transcription
factors, and is known to be required for the expression of
aSMA (12,29,38,39), whose expression is also stimulated
by FAPa (68,71). We suggest that the active FAK-PI3K
signaling necessary for aSMA and FAPa expression isFIGURE 8 Model of palladin, aSMA and FAPa regulation. Palladin is
regulated through integrin interactions in focal adhesions as well as growth
factor and nonreceptor tyrosine kinase signaling. Palladin has both f-actin
and non-f-actin interactions and plays a role in the regulation of aSMA
and FAPa gene expression. To see this figure in color, go online.
Biophysical Journal 109(2) 249–264also required for palladin expression. We also suggest that
palladin interactions with transcription factors, along with
FAK-PI3K signaling, are necessary for the expression of
FAPa and aSMA. Further, increasing aSMA expression is
associated with a decrease in palladin expression (38), sug-
gesting that aSMA protein inhibits palladin transcription,
creating an inhibitory feedback loop.
Palladin has two known roles in the cell—one in regu-
lating the actin cytoskeleton and adhesions and the other
in regulating gene expression. It also has two main localiza-
tion patterns—cytoplasmic (i.e., associated with the actin
cytoskeleton and/or at focal adhesions) (33,37,76,77) and
nuclear (40,41,77). We hypothesize that the localization of
palladin plays a role in the balance between these two
different activities. We suggest that in fibroblasts grown in
3D hydrogels, palladin is concentrated in the cytoplasmic
compartment at focal adhesions, which in our system
contain both b1 and b3 integrins. This sequesters palladin
and decreases the nuclear fraction, thus restricting its role
in regulating gene expression. b3 integrins have been shown
to play a role in the turnover of focal adhesions (78,79) and
when we block b3 integrins, palladin is redistributed from
the nucleus to the cytoplasmic compartment in part attribut-
able to sequestration at stabilized focal adhesions (Fig. 7).
On the other hand, blocking b1 integrins which should
lead to a reduction in focal adhesions, results in the nuclear
accumulation of palladin (Fig. 7). We suggest that by inter-
fering with b integrins, we alter the formation and/or turn-
over of focal adhesions, which leads to changes in the
distribution of palladin, which then leads to changes in pal-
ladin’s transcriptional regulation (74,80–82). Although the
exact mechanism of control of localization of palladin is still
unknown, phosphorylation of Ser507 by Akt1 is critical for
palladin to associate with actin (83) and Ser507 is in a C-ter-
minal domain of palladin that localizes to the nucleus when
expressed independently of the N-terminus of the protein
(42). This suggests that Akt1 phosphorylation may control
the localization of palladin, whereas the expression of palla-
din is controlled by Akt2 signaling, suggesting distinct roles
of Akt signaling in the control of palladin transcription and
regulation.
Phosphoinositide 3-kinase is a signal transduction
enzyme that is known to interact both with integrin
signaling via FAK and with other RTK such as growth factor
receptors, and it can also signal through protein kinase B
(Akt) (84–86). We hypothesize that if we inhibit the PI3K
binding partner FAK, or block FAK activation by blocking
b1 integrins, we shift the interaction of PI3K to its other
available partners, RTKs. We suggest that this shift in
PI3K association leads to a decrease in palladin transcrip-
tion by both reducing FAK-PI3K-Atk2 activity, which
has been shown to stimulate palladin expression, and by
increasing an unknown RTK pathway, perhaps by differen-
tial phosphorylation of Akt2, which has at least five
different phosphorylation sites (74,87). Concurrently, we
Fibroblast Activation in the TME 261suggest that a stimulation of palladin expression by an un-
known source of Akt2 activation—such as known PI3K in-
dependent Akt2 activators TNK2, Src, and PTK6—arises
from the shift toward growth factor related signaling, as
TNK2, Src, and PTK6 activation are linked to growth factor
signaling (88). This suggests that a shift from FAK-PI3K
toward RTK-PI3K activity inhibits palladin expression by
both inhibiting FAK-PI3K stimulatory activity and stimu-
lating RTK-PI3K inhibitory activity and stimulates palladin
expression by stimulating an unknown Akt2 activator.
Our complete model for palladin, aSMA and FAPa
expression is depicted in Fig. 8 (and Fig. S5 B) with the
effect of manipulations depicted in Fig. S5 A and predicted
magnitude of effect of manipulations upon palladin in
Table 2. Focal adhesions stimulate palladin expression
through FAK-PI3K. Palladin stimulates FAPa expression,
which in turn stimulates aSMA expression. aSMA in turn
inhibits palladin transcription. The association of palladin
with focal adhesions and the actin cytoskeleton regulates
its ability to stimulate FAPa and aSMA. All the while,
RTK signaling inhibits palladin expression while it has the
ability to also stimulate palladin expression through an un-
known PI3K independent mechanism.
The regulation of TGFb and FN-EDA expression appears
to be more straightforward. TGFb is a paradoxical growth
factor; in normal tissues, it acts as a tumor suppressor, but
in cancer, it plays a role in promoting metastasis (3). Inter-
estingly, TGFb expression does not change in our activated
fibroblasts. This is consistent, however, with reports sug-
gesting that TGFb induced myofibroblasts take more than
42 days to double their TGFb expression (49). Our results
do indicate that TGFb expression is regulated by FAK,
which is consistent with existing TGFb literature (89).
Our results also suggest that palladin plays a major role in
TGFb expression through both expression level and cyto-
plasmic/nuclear localization.
The fibronectin splice variant EDA is a variant of fibro-
nectin that contains an extra alternatively encoded type III
domain repeat. It is found only in insoluble secreted ECM
and its expression is usually limited to embryogenesis
(63). FN-EDA is induced by stiffness, but our data does
not directly indicate a role for FAK-PI3K signaling in itsTABLE 2 Model predictions for the change in palladin gene expres
Palladin FAK-PI3K Loss FAK: RTK RTK-PI3K
b1 integrin antibody YYYY YYYY 4
b3 integrin antibody 4 4 4
FAK inhibitor YYYY Y 4
PI3K inhibitor YYYY 4 [[
FAK and PI3K inhibitors YYYY Y [[
b1 antibody and PI3K inhibitor YYYY YYYY [[
FAK-PI3K: loss is the change because of the loss of signaling through the FAK
sociation with FAK versus other RTKs. RTK-PI3K inhibition is the change becau
TNK2 stimulation is the change because of stimulation of TNK2 by a shift in PI3
of the disassociation of palladin from focal adhesions (positive for disassociationexpression, despite previous reports suggesting that sig-
naling via PI3K-Akt-mTOR can stimulate FN-EDA expres-
sion (90). There does, however, appear to be a relationship
between FN-EDA and TGFb expression, similar to a recent
report in which increased TGFb expression leads to
increased FN-EDA, independent of PI3K signaling (91).
This may be because of FN-EDA stimulation by the
MAPK pathway (63) that is known to work synergistically
with the TGFb pathway (92).
Our model for TGFb and FN-EDA expression is depicted
in Fig. S5 B with the effect of manipulations depicted in
Fig. S5 C and predicted magnitude of effect of manipula-
tions upon palladin in Table S3. Simply, TGFb expression
is stimulated by FAK and palladin, and TGFb in turn stim-
ulates FN-EDA expression (91). For instance, when we
block b1 integrin, we significantly reduce the downstream
FAK-PI3K signaling, which stimulates palladin transcrip-
tion. This also leads to a dramatic shift in the interactions
of PI3K from FAK toward RTKs by eliminating the ability
of FAK to associate with b1 integrins (by reducing the for-
mation of focal adhesions). This causes a drastic increase in
RTK-associated palladin inhibition. This shift in PI3K
signaling, however, also increases PI3K independent palla-
din stimulation. Also, palladin localization shifts to the
nucleus, which allows for regulation of transcription, stimu-
lating FAPa and aSMA transcription. This stimulation
maintains aSMA protein levels, which in turn maintains
an inhibitory feedback on palladin transcription. Together,
this results in a net reduction in palladin transcription, over-
expression of FAPa, and maintenance of aSMA transcrip-
tion (Figs. 6 and 8, and Table 2). In the case of TGFb and
FN-EDA, blocking b1 integrin reduces the FAK signaling
necessary for TGFb transcription by both reducing focal ad-
hesions and further by inhibiting FAK. There is also less pal-
ladin being produced to stimulate production of TGFb, but
because of the nuclear localization of palladin, there is an
intense stimulation of TGFb production by palladin tran-
scriptional regulation. Together, this results in a dramatic in-
crease in TGFb transcription, which also leads to increased
FN-EDA expression (Figs. 6 and S5, and Table S3).
These results offer, to our knowledge, new insights into
the regulation of fibroblast activation by the ECM. Wesion due to inhibitory manipulations
Inhibition Unknown Stimulation Actin Association aSMA NET
[[ [[ 4 YYYY
4 4 [[ [[
[[ 4 [[ Y
4 4 [[ 4
[[ 4 [[ [
[[ [[ [[ 4
-PI3K pathway. FAK: RTK is the change because of any shift in PI3K as-
se of PI3K inhibition upon the RTK-PI3K inhibition of palladin expression.
K to favor growth factor signaling. Actin association is the change because
). aSMA is the change because of alteration of the level of aSMA inhibition.
Biophysical Journal 109(2) 249–264
262 McLane and Ligonobserve that an increase in matrix stiffness of ~fourfold
from ~200 Pa to ~800 Pa induces a change in fibroblast
phenotype to that of a myofibroblast that does not require
exogenous TGFb, is fibronectin and CCL dependent, and
converges chemical and mechanical signaling pathways
through CCR4 chemokine receptors, b1 and b3 integrins,
FAK, and PI3K, with palladin as a central node in these
pathways, to jointly control myofibroblast gene expression.SUPPORTING MATERIAL
Five figures and three tables are available at http://www.biophysj.org/
biophysj/supplemental/S0006-3495(15)00616-5.AUTHOR CONTRIBUTIONS
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